J.-S. Lee

461 total citations
17 papers, 310 citations indexed

About

J.-S. Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J.-S. Lee has authored 17 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in J.-S. Lee's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). J.-S. Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). J.-S. Lee collaborates with scholars based in South Korea, United States and Japan. J.-S. Lee's co-authors include Makoto Nishio, Hiroshi Tanaka, Yuichiro Ohe, Chong‐Jen Yu, Hiroaki Akamatsu, Nobuyuki Yamamoto, Naoki Inui, Shunichi Sugawara, Takamasa Yoshida and Yoshinobu Namba and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

J.-S. Lee

15 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.-S. Lee South Korea 7 268 200 66 44 37 17 310
Xue‐Wu Wei China 8 185 0.7× 177 0.9× 69 1.0× 26 0.6× 54 1.5× 13 287
Qing Chang China 7 239 0.9× 179 0.9× 55 0.8× 28 0.6× 32 0.9× 21 308
T-E. Ciuleanu Romania 11 266 1.0× 240 1.2× 57 0.9× 18 0.4× 46 1.2× 47 345
Christina J. Falcon United States 11 183 0.7× 215 1.1× 98 1.5× 23 0.5× 64 1.7× 22 304
Ying Cheng China 8 211 0.8× 102 0.5× 64 1.0× 59 1.3× 33 0.9× 48 269
J.C.-H. Yang Taiwan 5 263 1.0× 281 1.4× 94 1.4× 16 0.4× 46 1.2× 12 353
Linpeng Zheng China 10 207 0.8× 150 0.8× 77 1.2× 32 0.7× 71 1.9× 17 304
Dario Nicolella Italy 9 227 0.8× 158 0.8× 108 1.6× 28 0.6× 45 1.2× 16 332
Silvana Acquafredda Italy 6 159 0.6× 94 0.5× 42 0.6× 20 0.5× 40 1.1× 8 237
Rui Kitadai Japan 10 213 0.8× 161 0.8× 35 0.5× 18 0.4× 40 1.1× 27 296

Countries citing papers authored by J.-S. Lee

Since Specialization
Citations

This map shows the geographic impact of J.-S. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-S. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-S. Lee more than expected).

Fields of papers citing papers by J.-S. Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.-S. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-S. Lee. The network helps show where J.-S. Lee may publish in the future.

Co-authorship network of co-authors of J.-S. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of J.-S. Lee. A scholar is included among the top collaborators of J.-S. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-S. Lee. J.-S. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39. 1 indexed citations
2.
O’Byrne, Kenneth J., Makoto Nishio, Hiroshi Sakai, et al.. (2022). First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open. 7(1). 100394–100394. 14 indexed citations
3.
Sugawara, Shunichi, J.-S. Lee, Jin‐Hyoung Kang, et al.. (2021). Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Annals of Oncology. 32(9). 1137–1147. 135 indexed citations
4.
Ciuleanu, Tudor–Eliade, Adam Płużański, J.-S. Lee, et al.. (2021). OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1. Journal of Thoracic Oncology. 16(1). S2–S3. 2 indexed citations
5.
Reck, M., Stephen V. Liu, Aaron S. Mansfield, et al.. (2019). IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 30. v710–v711. 49 indexed citations
6.
Nishio, Makoto, Jun Ho Ji, Katsuyuki Hotta, et al.. (2019). Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. Annals of Oncology. 30. ix197–ix198. 3 indexed citations
7.
Gray, Jhanelle E., Nir Peled, Aleksandra Markovets, et al.. (2019). Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA. Annals of Oncology. 30. v921–v922. 4 indexed citations
8.
Kim, T.M., Chan‐Young Ock, Bhumsuk Keam, et al.. (2019). Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19). Annals of Oncology. 30. v628–v628. 29 indexed citations
9.
Cho, Byoung Chul, J.-S. Lee, Ji‐Youn Han, et al.. (2018). JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results. Annals of Oncology. 29. viii542–viii542. 14 indexed citations
10.
Deva, Sanjeev, J.-S. Lee, Chia‐Jui Yen, et al.. (2018). A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. Annals of Oncology. 29. x24–x25. 14 indexed citations
11.
Kang, Jin Hyoung, Byoung Chul Cho, D.-W. Kim, et al.. (2018). Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset. Annals of Oncology. 29. viii522–viii522. 1 indexed citations
12.
13.
Lee, J.-S., et al.. (2016). 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. Journal of Thoracic Oncology. 11(4). S113–S113. 35 indexed citations
14.
15.
Lee, J.-S., et al.. (2015). 461P Patients (Pts) with advanced NSCLC from Korea treated with pembrolizumab (Pembro) in KEYNOTE-001. Annals of Oncology. 26. ix125–ix125.
16.
Lee, J.-S., Ji‐Youn Han, Jie‐Hyun Kim, et al.. (2015). 425PD Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC. Annals of Oncology. 26. ix125–ix125. 5 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xue‐Wu Wei Breakdown of academic impact, for papers by Qing Chang Breakdown of academic impact, for papers by T-E. Ciuleanu Breakdown of academic impact, for papers by Christina J. Falcon Breakdown of academic impact, for papers by Ying Cheng Breakdown of academic impact, for papers by J.C.-H. Yang Breakdown of academic impact, for papers by Linpeng Zheng Breakdown of academic impact, for papers by Dario Nicolella Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Rui Kitadai
Rankless by CCL
2026